How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

Research output: Contribution to journal › Article › peer-review

Authors

Colleges, School and Institutes

Details

Original languageEnglish
JournalBritish Journal of Haematology
Publication statusE-pub ahead of print - Oct 2020
Save citation Saved citations (0)

Copy the text from this field...

View graph of relations

DOI

By the same authors

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses

Sylvie Freeman, 23 Dec 2020, In: Journal of Clinical Oncology . p. JCO2001170

Research output: Contribution to journal › Article › peer-review

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Sylvie Freeman, Oct 2020, In: JAMA Oncology.

Research output: Contribution to journal › Article › peer-review

Less is not necessarily more: toward a rational selection of the conditioning regimen in acute myeloid leukemia

Sylvie Freeman, 20 Apr 2020, In: Journal of Clinical Oncology . 38, 12, p. 1249-1251 3 p.

Research output: Contribution to journal › Editorial